Report from Annual General Meeting in Intervacc

Intervacc AB (publ) has held its Annual General Meeting (”AGM”) on Wednesday 7 June 2023, at which the following resolutions were made.

Adoption of the income statement and balance sheet

The AGM adopted the Board of Directors’ submitted income statement and balance sheet for the parent company and the group for the financial year 2022.

Appropriation of the company’s profit or loss

The AGM resolved, in accordance with the Board of Directors’ proposal, that no dividend shall be paid for the financial year 2022, and that the result shall be balanced in a new account.

Discharge from liability towards the members of the Board of Directors and the CEO

The AGM resolved to discharge each of the members of the Board of Directors and the CEO from liability for the financial year 2022.

Board of Directors and auditor

The AGM resolved, in accordance with the Nomination Committee’s proposal, that the Board of Director shall consist of seven Board members without any deputies.

The AGM resolved, in accordance with the Nomination Committee’s proposal, to re-elect Björn Sjöstrand, Bengt Guss, Stefan Ståhl, Niels Holck, Ed Torr and Michela De Carli, and to elect Boel Sundvall, as Board members for the period up to and including the next AGM. Björn Sjöstrand was re-elected as the Board of Directors’ chairperson for the period up to and including the next AGM.

The AGM resolved, in accordance with the Nomination Committee’s proposal, that the fees to the Board of Directors shall be paid with SEK 280,000 to the Board of Directors’ chairperson and SEK 130,000 to each of the other Board members.

The AGM resolved, in accordance with the Nomination Committee’s proposal, to re-elect the registered public accounting firm Öhrlings PricewaterhouseCoopers AB as the company’s auditor for the period up to and including the next AGM, which intends to appoint the authorised public accountant Leonard Daun as auditor in charge.

The AGM resolved that fees to the auditor shall be paid according to the current account.

Authorisation regarding issues

The AGM resolved, in accordance with the Board of Directors’ proposal, to authorise the Board of Directors, within the limits of the Articles of Association, with or without deviation from the shareholders’ preferential rights, on one or more occasions, until the next AGM, to resolve to increase the company’s share capital through issues of new shares, warrants and/or convertibles in the company. The total number of shares covered by such new issues may correspond to a total of no more than ten (10) percent of the shares in the company at the time of the AGM 2023.

 

For more information please contact:  

Andreas Andersson, CEO

Phone: +46 (0)8 120 10 601, Cell: +46 (0)73 335 99 70

E-mail: [email protected]

 

The information was submitted for publication, through the agency of the contact person set out above on June 7, 2023, 20.30 CET.

 

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company’s vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the NASDAQ First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

 

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: [email protected], Phone: +46 (0)8 – 684 211 10